China Pharma (CPHI) vs Elicio Therapeutics (ELTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
China Pharma (CPHI) has outperformed Elicio Therapeutics (ELTX) over the past year, losing 51.8% versus a loss of 82.8%. Over five years, ELTX leads with a -97.9% price change compared with -99.7% for CPHI. Elicio Therapeutics is the larger company by market cap ($50.1 million vs $37.1 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPHI | ELTX |
|---|---|---|
| Share price | $0.8635 | $1.91 |
| Market cap | $37.15M | $50.07M |
| 1-day change | -10.05% | +5.25% |
| YTD return | -20.66% | -77.26% |
| 1-year return | -51.76% | -82.79% |
| 5-year return | -99.65% | -97.92% |
| EPS (TTM) | $-0.42 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.19 | $16.00 |
| 52-week low | $0.38 | $1.71 |
| Distance from 52-week high | -95.50% | -88.09% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +617.59% |
| Average volume | 5.81M | 340.72K |
| Shares outstanding | 43.02M | 26.28M |
| Employees | 215 | 33 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CPHI has outperformed ELTX by 31.0 percentage points over the past year.
About China Pharma
CPHI stock →China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.
Health Care · Biotechnology: Pharmaceutical Preparations · 215 employees
About Elicio Therapeutics
ELTX stock →Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
CPHI vs ELTX FAQ
Which is bigger, China Pharma or Elicio Therapeutics?
Elicio Therapeutics (ELTX) is larger, with a market capitalization of $50.07M compared with $37.15M for China Pharma (CPHI).
Which stock has performed better over the past year, CPHI or ELTX?
CPHI returned -51.76% over the past 12 months, compared with -82.79% for ELTX (price return, excluding dividends). Past performance does not predict future results.
Are China Pharma and Elicio Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.